Inhibition of dipeptidylpeptidase-IV by 2-S-cyanopyrrolidine inhibitors of prolyl endopeptidase

Мұқаба

Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Тек жазылушылар үшін

Аннотация

Many regulatory neuropeptides contain a large amount of proline residues. The unique proline peptide bond conformation protects these peptides from enzymatic degradation; therefore enzymes cleaving the proline peptide bonds in neuropeptides are of particular interest. The abnormal activity of serine peptidases that cleave peptides at the carboxyl group of proline residues prolyl endopeptidase (PEP) and dipeptidyl peptidase IV (DPP-IV) were observed in patients with anxiety disorders. PEP is involved in the maturation and degradation of neuropeptides and peptide hormones, it also is associated with the regulation of blood pressure and various disorders of the central nervous system. DPP-IV is involved in many physiological processes, in particular in glucose homeostasis in type II diabetes and immunity. When studying the metabolism of the N-acyl derivative of the aminoacyl-2-cyanopyrrolidine PEP inhibitor a decreasing in the activity of DPP-IV at the initial time was detected. This was an unexpected effect observed for inhibitors of the general formula X-Y-2-S-cyanopyrrolidine, where X represents the N-protective group and Y represents the amino acid (any besides glycine and proline). Molecular dynamics simulations of inhibitor complexes with proteases revealed the possibility of PEP inhibitors binding in the DPP-IV active site with hydrogen bonds and hydrophobic interactions that allow linkage of the nitrile group with the catalytic serine residue in the DPP-IV active site. The present study opens the prospect of creating new pharmacologically active ligands of PEP and DPP-IV.

Толық мәтін

Рұқсат жабық

Авторлар туралы

G. Makarov

South Ural State University

Хат алмасуға жауапты Автор.
Email: makarovgi@susu.ru
Ресей, prosp. Lenina 76, Chelyabinsk, 454080

N. Zolotov

Research Zakusov Institute of Pharmacology

Email: makarovgi@susu.ru
Ресей, ul. Baltiyskaya 8, Moscow, 125315

V. Pozdnev

Institute of Biomedical Chemistry

Email: makarovgi@susu.ru
Ресей, ul. Pogodinskaya 10/8, Moscow, 119121

Әдебиет тізімі

  1. Role of Proteases in the Pathophysiology of Neurodegenerative Diseases / Eds. Lajtha A., Banik N. New York: Kluwer Academic, 2002. https://doi.org/10.1007/b111075
  2. Holmes A., Heilig M., Rupniak N.M., Steckler T., Griebel G. // Trends Pharmacol. Sci. 2003. V. 24. P. 580–588. https://doi.org/10.1016/j.tips.2003.09.011
  3. Thornberry N., Weber A. // Curr. Top. Med. Chem. 2007. V. 7. P. 557–568. https://doi.org/10.2174/156802607780091028
  4. Krupina N.A., Khlebnikova N.N., Orlova I.N., Grafova V.N., Smirnova V.S., Rodina V.I., Kukushkin M.L., Kryzhanovsky G.N. // Bull. Exp. Biol. Med. 2010. V. 149. P. 479–484. https://doi.org/10.1007/s10517-010-0975-3
  5. Maes M., Goossens F., Scharpé S., Meltzer H.Y., D’Hondt P., Cosyns P. // Biol. Psychiatry. 1994. V. 35. P. 545–552. https://doi.org/10.1016/0006-3223(94)90101-5
  6. Krupina N., Khlebnikova N., Zolotov N., Kushnareva E., Bogdanova N., Orlova I. // In: Encyclopedia of Pharmacology Research / Eds. Cheng D., Liu G. New York: Nova Science Publ., 2013. P. 137–156. https://novapublishers.com/shop/encyclopedia-of-pharmacology-research-2-volume-set/
  7. Khlebnikova N.N., Krupina N.A., Bogdanova N.G., Zolotov N.N., Kryzhanovskii G.N. // Bull. Exp. Biol. Med. 2009. V. 147. P. 26–30. https://doi.org/10.1007/s10517-009-0458-6
  8. Krupina N.A., Kushnareva E.Y., Khlebnikova N.N., Zolotov N.N., Kryzhanovskii G.N. // Bull. Exp. Biol. Med. 2009. V. 147. P. 285–290. https://doi.org/10.1007/s10517-009-0493-3
  9. Syunyakov T., Zolotov N., Neznamov G. // Eur. Neuropsychopharmacol. 2017. V. 27. P. S985. https://doi.org/10.1016/S0924-977X(17)31734-0
  10. Yakovleva A., Zolotov N., Sokolov O., Kost N., Kolyasnikova K., Mikheeva I.G. // Neuropeptides. 2015. V. 52. P. 113–117. https://doi.org/10.1016/j.npep.2015.05.001
  11. Krupina N.A., Bogdanova N.G., Khlebnikova N.N., Zolotov N.N., Kryzhanovskii G.N. // Bull. Exp. Biol. Med. 2013. V. 154. P. 606–609. https://doi.org/10.1007/s10517-013-2010-y
  12. Yoshimoto T., Kado K., Matsubara F., Koriyama N., Kaneto H., Tsuru D. // J. Pharmacobiodyn. 1987. V. 10. P. 730–735. https://doi.org/10.1248/bpb1978.10.730
  13. Pozdnev V.F. // Tetrahedron Lett. 1995. V. 36. P. 7115–7118. https://doi.org/10.1016/0040-4039(95)01412-B
  14. Cobb A.J.A., Shaw D.M., Longbottom D.A., Gold J.B., Ley S.V. // Org. Biomol. Chem. 2005. V. 3. P. 84–96. https://doi.org/10.1039/b414742a
  15. Cummins P.M., Dowling O., O’Connor B.F. // In: Methods in Molecular Biology / Eds. Walls D., Loughran S.T. New York: Humana Press. 2011. P. 215–228. https://doi.org/10.1007/978-1-60761-913-0_12
  16. Haffner C.D., Diaz C.J., Miller A.B., Reid R.A., Madauss K.P., Hassell A., Hanlon M.H., Porter D.J., Becherer J.D., Carter L.H. // Bioorg. Med. Chem. Letters. 2008. V. 18. P. 4360–4363. https://doi.org/10.1016/j.bmcl.2008.06.067
  17. Pissarnitski D.A., Zhao Z., Cole D., Wu W.-L., Domalski M., Clader J.W., Scapin G., Voigt J., Soriano A., Kelly T., Powles M.A., Yao Z., Burnett D.A. // Bioorg. Med. Chem. 2016. V. 24. P. 5534–5545. https://doi.org/10.1016/j.bmc.2016.09.007
  18. Ruiz-Carmona S., Alvarez-Garcia D., Foloppe N., Garmendia-Doval A.B., Juhos S., Schmidtke P., Barril X., Hubbard R.E., Morley S.D. // PLoS Comput. Biol. 2014. V. 10. P. e1003571. https://doi.org/10.1371/journal.pcbi.1003571
  19. Szeltner Z., Rea D., Renner V., Juliano L., Fulop V., Polgar L. // J. Biol. Chem. 2003. V. 278. P. 48786– 48793. https://doi.org/10.1074/jbc.M309555200
  20. Venalainen J.I., Garcia-Horsman J.A., Forsberg M.M., Jalkanen A., Wallen E.A., Jarho E.M., Christiaans J.A., Gynther J., Mannisto P.T. // Biochem. Pharmacol. 2006. V. 71. P. 683–692. https://doi.org/10.1016/j.bcp.2005.11.029
  21. Cunningham D.F., O’Connor B. // Biochim. Biophys. Acta. 1997. V. 1343. P. 160–186. https://doi.org/10.1016/s0167-4838(97)00134-9
  22. van der Spoel D., Lindahl E., Hess B., Groenhof G., Mark A., Berendsen H. // J. Comput. Chem. 2005. V. 26. P. 1701–1718. https://doi.org/10.1002/jcc.20291
  23. van der Spoel D., Lindahl E., Hess B., Kutzner C. // J. Chem. Theory Comput. 2008. V. 4. P. 435–447. https://doi.org/10.1021/ct700301q
  24. Hornak V., Abel R., Okur A., Strockbine B., Roitberg A., Simmerling C. // Proteins. 2006. V. 65. P. 712–725. https://doi.org/10.1002/prot.21123
  25. Bayly C.I., Cieplak P., Cornell W., Kollman P.A. // J. Phys. Chem. 1993. V. 97. P. 10269–10280. https://doi.org/10.1021/j100142a004
  26. Bussi G., Donadio D., Parrinello M. // J. Chem. Phys. 2007. V. 126. P. 014107–014106. https://doi.org/10.1063/1.2408420
  27. Berendsen H., Postma J., van Gunsteren W., DiNola A., Haak J. // J. Chem. Phys. 1984. V. 81. P. 3684–3690. https://doi.org/10.1063/1.448118
  28. Darden T., York D., Pedersen L. // J. Chemical Physics. 1993. V. 98. P. 10089–10092. https://doi.org/10.1063/1.464397
  29. Horn H.W., Swope W.C., Pitera J.W., Madura J.D., Dick T.J., Hura G.L., Head-Gordon T. // J. Chem. Phys. 2004. V. 120. P. 9665–9678. https://doi.org/10.1063/1.1683075
  30. Joung I.S., Cheatham T.E. // J. Phys. Chem. B. 2008. V. 112. P. 9020–9041. https://doi.org/10.1021/jp8001614
  31. Hess B., Bekker H., Berendsen H.J.C., Fraaije J.G.E.M. // J. Comput. Chem. 1997. V. 18. P. 1463–1472. https://doi.org/10.1002/(SICI)1096-987X (199709)18:12<1463::AID-JCC4>3.0.CO;2-H
  32. Makarov G.I., Sumbatyan N.V., Bogdanov A.A. // Biochemistry (Moscow). 2017. V. 82. P. 925–932. https://doi.org/10.1134/S0006297917080077
  33. Daura X., Gademann K., Jaun B., Seebach D., van Gunsteren W.F., Mark A.E. // Ang. Chem. Int. Ed. 1999. V. 38. P. 236–240. https://doi.org/10.1002/(SICI)1521-3773(19990115) 38:1/2<236::AID-ANIE236>3.0.CO;2-M
  34. Kabsch W., Sander C. // Biopolymers. 1983. V. 22. P. 2577–2637. https://doi.org/10.1002/bip.360221211

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу
2. Supplementary
Жүктеу (634KB)
Метадеректер
3. Fig. 1. Structures of peptidase inhibitors studied in this work.

Жүктеу (205KB)
Метадеректер
4. Fig. 2. Hydrogen bonds formed by inhibitors with the active site of PEP. AA is the corresponding amino acid residue of the inhibitor, Protect is the protecting group. See also Table S1 in the supplementary material.

Жүктеу (120KB)
Метадеректер
5. Fig. 3. Conformations of pyrrolidone prolyl endopeptidase inhibitors (shown in dark blue) in the active site of PEP obtained by molecular dynamics simulation. Hydrogen bonds are shown by black dotted lines. The near hydrophobic zone is shown in yellow, the hydrophobic cavity in blue, and the negative protrusion in red. (a) – HGlyPrn; (b) – CbzGlyPrn; (c) – CbzMetPrn; (d) – SucMetPrn.

Жүктеу (276KB)
Метадеректер
6. Fig. 4. Conformations of pyrrolidone prolyl endopeptidase inhibitors (shown in dark blue) in the active site of DPP4 obtained by molecular dynamics simulation. Hydrogen bonds are shown by black dotted lines. The near hydrophobic zone is shown in yellow, the hydrophobic cavity in blue, and the negative protrusion in red. (a) – HGlyPrn; (b) – CbzGlyPrn; (c) – CbzMetPrn; (d) – SucMetPrn.

Жүктеу (256KB)
Метадеректер
7. Fig. 5. General procedure for the synthesis of N-protected dipeptide carbonitriles. R1 is an amino acid side chain, R2 is tert-butyl or benzyl.

Жүктеу (113KB)
Метадеректер

© Russian Academy of Sciences, 2024